Aiosyn enhances its AI-powered quality control solution to detect white balance issues
Nijmegen, the Netherlands – Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, has announced the latest advancement in its automated quality control (QC) algorithm. AiosynQC, which automatically recognizes and flags the most common artifacts in hematoxylin and eosin (H&E) and immunohistochemistry (IHC) digital slides, now includes the ability to detect white balance issues. This new feature is designed to identify these problems without the need to manually review all slides and help technicians calibrate scanners more promptly.
It is crucial for scanned slides to represent accurately the original glass slide. Factors such as color sensor drift, glass slide variations, incorrect color normalization, and different illumination settings can lead to images that appear too dark and do not accurately reflect the sample. When this occurs, affected slides should be rescanned, as such white balance problems would hinder or prevent an accurate diagnosis, affecting both pathologist reviews and downstream algorithms used in diagnostic processes. AiosynQC‘s latest feature allows laboratories to identify and correct these issues more efficiently.
“This new feature, developed in response to customer requests, enables laboratories to efficiently detect white balance issues, ensuring higher-quality slides while reducing manual effort. It underscores our commitment to delivering AI-driven solutions that address real user needs.”David Tellez, CTO of Aiosyn
AiosynQC is a modular and flexible solution offered as a service that can be integrated into existing digital pathology software and deployed through the cloud or on-premise installation. The product helps laboratories to ensure that only high-quality images are used by pathologists, technicians, and researchers. By flagging cases before presentation to a pathologist, the algorithm reduces the time that is currently used to manually check for artifacts in whole slide images, thereby improving the efficiency of the QC process. These quality checks are also available through external digital slide quality assessments with AiosynQC Pulse for labs that are seeking insights into their slide quality without software integration.
This latest enhancement is part of Aiosyn’s ongoing efforts to expand the capabilities of its automated QC solution. With additional features in development, Aiosyn remains focused on driving innovation to streamline pathology workflows.
Learn more
To learn more about AiosynQC and explore opportunities to test the algorithm on your whole slide images, contact Aiosyn at contact@aiosyn.com.
Figure 1. Types of artifacts identified by AiosynQC.
About Aiosyn
Based in the Netherlands, Aiosyn develops precision pathology software for breast cancer and kidney disease, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.
AiosynQC
AiosynQC is not a medical device under the EU IVDR and the UK MDR 2002. It is not intended to be used as an accessory to, nor is it necessary to be used in combination with, any AI or other medical devices to specifically enable them to meet their intended purpose or directly assist in their functionality. AiosynQC is for Research Use Only (RUO) in the United States or any other jurisdiction.
SOURCE: Aiosyn
